ID   MM415
AC   CVCL_2608
SY   MM 415
DR   BioSample; SAMN07624429
DR   cancercelllines; CVCL_2608
DR   CBA; CBA-1351
DR   Cell_Model_Passport; SIDM01907
DR   Cosmic; 889021
DR   Cosmic; 928751
DR   Cosmic; 2159439
DR   DepMap; ACH-001569
DR   ECACC; 10092319
DR   GEO; GSM162933
DR   GEO; GSM226671
DR   Progenetix; CVCL_2608
DR   Wikidata; Q54906126
RX   PubMed=9354451;
RX   PubMed=10070891;
RX   PubMed=15048078;
RX   PubMed=17363583;
RX   PubMed=17516929;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; DepMap=ACH-001569).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): CBA=CBA-1351; DepMap=ACH-001569
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 9,13
ST   D16S539: 11
ST   D18S51: 14,20
ST   D19S433: 14,15.2
ST   D21S11: 27,28
ST   D2S1338: 17,19
ST   D3S1358: 14,15
ST   D5S818: 11
ST   D7S820: 9,11
ST   D8S1179: 14
ST   FGA: 23,25
ST   Penta D: 11,13
ST   Penta E: 10,12
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 23
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=10070891; DOI=10.1038/sj.bjc.6690147;
RA   Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.;
RT   "p53 mutations in human cutaneous melanoma correlate with sun exposure
RT   but are not always involved in melanomagenesis.";
RL   Br. J. Cancer 79:921-926(1999).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//